Research and Markets (http://www.researchandmarkets.com/research/6t3xxh/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Cancer-Pipeline Insights, 2016" report to their offering.

Metastatic Renal Cell Cancer-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Metastatic Renal Cell Cancer. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Renal Cell Cancer.

The report also assesses the Metastatic Renal Cell Cancer therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Metastatic Renal Cell Cancer
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Metastatic Renal Cell Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Cancer and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Metastatic Renal Cell Cancer Overview
  2. Metastatic Renal Cell Cancer Pipeline Therapeutics
  3. Metastatic Renal Cell Cancer Therapeutics under Development by Companies
  4. Metastatic Renal Cell Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Metastatic Renal Cell Cancer Phase II Products
  7. Metastatic Renal Cell Cancer Phase I and IND Filed Products
  8. Metastatic Renal Cell Cancer Discovery and Pre-Clinical Stage Products
  9. Metastatic Renal Cell Cancer - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Metastatic Renal Cell Cancer - Discontinued Products
  15. Metastatic Renal Cell Cancer - Dormant Products
  16. Companies Involved in Therapeutics Development for Metastatic Renal Cell Cancer

For more information visit http://www.researchandmarkets.com/research/6t3xxh/metastatic_renal